Lawrence P. Carter

3.1k total citations
38 papers, 1.5k citations indexed

About

Lawrence P. Carter is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lawrence P. Carter has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cognitive Neuroscience, 12 papers in Experimental and Cognitive Psychology and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lawrence P. Carter's work include Sleep and Wakefulness Research (17 papers), Sleep and related disorders (12 papers) and Forensic Toxicology and Drug Analysis (9 papers). Lawrence P. Carter is often cited by papers focused on Sleep and Wakefulness Research (17 papers), Sleep and related disorders (12 papers) and Forensic Toxicology and Drug Analysis (9 papers). Lawrence P. Carter collaborates with scholars based in United States, Netherlands and Canada. Lawrence P. Carter's co-authors include Roland R. Griffiths, Miriam Z. Mintzer, Wouter Koek, Charles P. France, K. Michael Cummings, Jed Black, Jane Gorsline, Daniel Pardi, Jack E. Henningfield and Yuan Lü and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Annals of Neurology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Lawrence P. Carter

37 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence P. Carter United States	21	551	472	389	379	265	38	1.5k
Malcolm S. Reid United States	27	448 0.8×	400 0.8×	261 0.7×	1.2k 3.3×	72 0.3×	44	2.3k
Kory Schuh United States	27	665 1.2×	435 0.9×	337 0.9×	317 0.8×	54 0.2×	58	2.4k
Joshua A. Lile United States	28	426 0.8×	133 0.3×	216 0.6×	1.3k 3.4×	260 1.0×	102	2.0k
Chandni Hindocha United Kingdom	28	457 0.8×	248 0.5×	216 0.6×	644 1.7×	158 0.6×	52	2.4k
Maximilian Pilhatsch Germany	20	211 0.4×	102 0.2×	138 0.4×	214 0.6×	197 0.7×	54	1.3k
Jillian H. Broadbear Australia	22	123 0.2×	185 0.4×	162 0.4×	526 1.4×	70 0.3×	86	1.4k
L. D. Chait United States	26	373 0.7×	296 0.6×	154 0.4×	909 2.4×	210 0.8×	46	1.9k
Ziva D. Cooper United States	33	278 0.5×	373 0.8×	140 0.4×	1.0k 2.7×	429 1.6×	103	2.9k
Kirsten C. Morley Australia	28	236 0.4×	109 0.2×	192 0.5×	851 2.2×	340 1.3×	107	2.5k
Alison Oliveto United States	28	336 0.6×	272 0.6×	283 0.7×	1.1k 3.0×	198 0.7×	103	2.5k

Countries citing papers authored by Lawrence P. Carter

Since Specialization

Citations

This map shows the geographic impact of Lawrence P. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence P. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence P. Carter more than expected).

Fields of papers citing papers by Lawrence P. Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence P. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence P. Carter. The network helps show where Lawrence P. Carter may publish in the future.

Co-authorship network of co-authors of Lawrence P. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence P. Carter. A scholar is included among the top collaborators of Lawrence P. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence P. Carter. Lawrence P. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ward, Michael P., et al.. (2024). Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(1). e12452–e12452. 6 indexed citations

Vinckenbosch, Frederick, Gert Jan Lammers, Sebastiaan Overeem, et al.. (2022). Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial. Human Psychopharmacology Clinical and Experimental. 38(1). e2858–e2858. 5 indexed citations

Devine, Jaime K., Lindsay P. Schwartz, Steven R. Hursh, et al.. (2022). Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions. Neurology and Therapy. 12(1). 249–265.

Weaver, Terri E., Christopher L. Drake, Heike Beneš, et al.. (2020). Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Annals of the American Thoracic Society. 17(8). 998–1007. 31 indexed citations

Thorpy, Michael J., Colin M. Shapiro, Geert Mayer, et al.. (2019). A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Annals of Neurology. 85(3). 359–370. 110 indexed citations

Carter, Lawrence P., et al.. (2019). Pregnancy and Contraception Experiences in Women With Narcolepsy: A Narcolepsy Network Survey. Journal of Clinical Sleep Medicine. 15(10). 1421–1426. 5 indexed citations

Schweitzer, Paula K., Russell Rosenberg, Gary Zammit, et al.. (2018). Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 199(11). 1421–1431. 111 indexed citations

Baladi, Michelle, Michael J. Forster, Michael B. Gatch, et al.. (2018). Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 366(2). 367–376. 74 indexed citations

Ruoff, Chad, Richard Bogan, Neil T. Feldman, et al.. (2017). Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes. Sleep Medicine. 35. 12–16. 7 indexed citations

10.

Carter, Lawrence P., Christine Acebo, & Ann Kim. (2014). Patients' Journeys to a Narcolepsy Diagnosis: A Physician Survey and Retrospective Chart Review. Postgraduate Medicine. 126(3). 216–224. 21 indexed citations

11.

Carter, Lawrence P., et al.. (2012). Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug and Alcohol Dependence. 128(3). 206–213. 22 indexed citations

12.

O’Connor, Richard J., Maansi Bansal‐Travers, Lawrence P. Carter, & K. Michael Cummings. (2012). What would menthol smokers do if menthol in cigarettes were banned? Behavioral intentions and simulated demand. Addiction. 107(7). 1330–1338. 76 indexed citations

13.

Reissig, Chad J., et al.. (2012). High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology. 223(1). 1–15. 63 indexed citations

14.

Carter, Lawrence P., Bethea A. Kleykamp, Roland R. Griffiths, & Miriam Z. Mintzer. (2012). Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology. 226(1). 53–63. 17 indexed citations

15.

Carter, Lawrence P. & Roland R. Griffiths. (2009). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence. 105. S14–S25. 158 indexed citations

16.

Carter, Lawrence P., Roland R. Griffiths, & Miriam Z. Mintzer. (2009). Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology. 206(1). 141–154. 32 indexed citations

17.

Carter, Lawrence P., Daniel Pardi, Jane Gorsline, & Roland R. Griffiths. (2009). Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem®): Differences in characteristics and misuse. Drug and Alcohol Dependence. 104(1-2). 1–10. 104 indexed citations

18.

Carter, Lawrence P., Brian D. Richards, Miriam Z. Mintzer, & Roland R. Griffiths. (2006). Relative Abuse Liability of GHB in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects of Supratherapeutic Doses of Triazolam, Pentobarbital, and GHB. Neuropsychopharmacology. 31(11). 2537–2551. 70 indexed citations

19.

Koek, Wouter, Lawrence P. Carter, R. J. Lamb, et al.. (2005). Discriminative Stimulus Effects of γ-Hydroxybutyrate (GHB) in Rats Discriminating GHB from Baclofen and Diazepam. Journal of Pharmacology and Experimental Therapeutics. 314(1). 170–179. 21 indexed citations

20.

Mennemeier, Mark, et al.. (1994). Contributions of the parietal and frontal lobes to sustained attention and habituation. Neuropsychologia. 32(6). 703–716. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact